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Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients
with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30mg/m2
i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5mg/kg i.v. every 2 weeks.
Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a
palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only ﬁve
patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an eﬀective and
well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.
1.Introduction
The results of two large randomised trials have provided
substantial support in favor of the role of chemotherapy in
the treatment of castrate-resistant prostate cancer (CRPC)
by demonstrating that docetaxel (D) and prednisone (P)
improve survival in comparison with older regimens and
signiﬁcantly improve the quality of life [1, 2]. Therefore,
D has become the ﬁrst-line standard of care for metastatic
CRPC, with PSA responses of about 50% and median
survivals of usually less than 20 months.
Patients with CRPC who progress after D treatment may
be considered for a second-line chemotherapy, especially if
they have a reasonable performance status, have symptoms,
and/or are likely to soon develop symptoms for their
disease. In this setting, a recent randomized phase III trial
demonstrated that cabazitaxel, a tubuline-binding taxane
drug, improved survival in metastatic CRPC patients with
progressive disease after D-treatment, with a 30% reduction
in the risk of death compared with mitoxantrone taken as
control group [3].
D resistance is a common problem in the treatment of
many tumors including CRPC, and the development of new
drugs that may overcome such resistance is important to
extend D activity [4].
Angiogenesis is an important process for growth, pro-
gression, and metastasis of solid tumors, and the inhibitor of
the vascular endothelial growth factor (VEGF) bevacizumab2 Prostate Cancer
(Bev) is currently approved for the treatment of colon, lung,
breast,andclearcellrenalcarcinomainthemetastaticsetting
[5].
In addition, preclinical data demonstrated that VEGF
inhibition may also prevent further tumor growth of the
prostate cancer cell line DU 145 implanted in nude mice,
andpreliminaryclinicalstudiessuggestedthatBevcombined
with chemotherapy is tolerable and has promising activity in
CRPC patients [6, 7].
Although Bev achieved no PSA response when it was
used in monotherapy, interesting results were reported by
the combination of Bev with D and estramustine as ﬁrst-line
treatment in a previous study of the Cancer and Leukemia
Group B [8]. Moreover, a recent study described promising
data in terms of PSA response and objective response in
pretreated patients with CRPC receiving D and Bev [9]. On
these previous experiences, and in the hypothesis that Bev
may overcome the resistance to D, we tested the activity
and tolerability of Bev combined with D in CRPC patients
with disease progression during or after D-based ﬁrst-line
chemotherapy.
2. Patientsand Methods
2.1. Eligibility Criteria. This phase II study involved patients
with histologically conﬁrmed, measurable, or evaluable
advanced prostatic adenocarcinoma who had progressed
while on D or within 60 days after the last D dose. This
last eligibility criterium, together with a minimum of 3
months of D-based chemotherapy as ﬁrst-line treatment,
was required in order to better elucidate the beneﬁt of the
addition of Bev. Patients were admitted to the chemotherapy
protocol provided that they met at least one of the following
criteria: a positive bone scan a ≥25% increase in PSA (PSA
higher than 2ng/mL) in comparison with baseline on two
successive occasions separated by at least two weeks for
patients without measurable disease; new metastatic lesions
revealed by a bone scan; and a ≥25% increase in a bidi-
mensionally measurable tumor mass. All of the patients had
to have an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of ≤ 2, adequate hematological
(leukocytes ≥ 3000/mm3; hemoglobin ≥ 10g/dL, platelets
≥ 100,000/mm3), renal (serum creatinine ≤ 2.0mg/dL), and
hepatic function (serum bilirubin ≤2.0mg/dL; Table 1).
Patients were excluded if they had not received prior
D-based chemotherapy or if they had congestive heart
failure, a recent myocardial infarction, or any other previous
malignant diseases except basal cell carcinoma of the skin.
Bisphosphonates were admitted in all of patients who
presented with bone metastases.
ThestudywasapprovedbytheethicalcommitteeofSiena
University, and all patients provided their written informed
consent.
2.2. Treatment Plan. Treatment consisted of D 30mg/m2 as
a 30-minute intravenous infusion, using a schedule of four
consecutiveweeklyadministrationsfollowedbya2-weekrest
interval, in addition to Bev 5mg/kg intravenously every 2
Table 1: Main eligibility criteria.
Histologically conﬁrmed advanced prostatic carcinoma
Progression while on D or within 60 days after the last D dose
A positive bone scan and a ≥25% increase in PSA in
comparison with baseline
New metastatic lesions revealed by a bone scan
A ≥25% increase in bidimensionally measurable tumor mass
ECOG PS of ≤2
Leukocytes ≥3000/mm3,h a e m o g l o b i n≥ 10g/dL, platelets
≥ 100.000/mm3
Serum creatinine ≤ 2.0mg/dL; serum bilirubin ≤ 2.0mg/dL
weeks. Premedication consisted of P 10mg p.o. (12h before,
at the time of, and 12h after D administration). Cycles
were administered if serum leukocytes were ≥3000/mm3,
granulocytes > 1500/mm3, and platelets > 100,000/mm3.
Ondansetron 8mg was administered at the beginning of
each treatment cycle as antiemetic medication. The patients




Bev could be continued at the investigator’s discretion, or
until disease progression or unacceptable toxicity.
2.3. Response Assessments. Tumor response in patients with
measurable lesions was evaluated using the RECIST criteria
[10]. Serum PSA was measured every three weeks: a PSA
response was deﬁned as a reduction from baseline of at
least 50% for at least three weeks whereas PSA progression
was deﬁned as an increase from nadir of at least 25%
and ≥2ng/mL [11]. Pain symptomatology was measured
at baseline and then every 6 weeks by the McGill Melzack
Pain Questionnaire, and pain response was deﬁned as a 2-
point reduction in the 6-point present pain intensity scale
(or the complete disappearance of pain if the initial score
was 1+) [12]. These results had to be maintained at two
consecutive evaluations made at least 3 weeks apart and
without any increase in analgesic consumption. The patients
were asked to classify the average pain level during the
previous 24h. We used a translated form of the McGill
Melzack Questionnaire to which the “reconstruction-based
methodology”hasbeenapplied[13].Analgesicconsumption
was based on the average daily quantities taken by the patient
during the previous week, and assigned oral morphine
equivalents before analysis [14].
The laboratory studies (blood and platelet counts, and a
comprehensive screening proﬁle) were performed at baseline
and every three weeks, and the patients underwent a weekly
c o m p l e t eb l o o dc e l lc o u n ta n de l e c t r o l y t e sp r o ﬁ l eb e f o r e
chemotherapy.
The imaging studies included abdominal and pelvic CT
or magnetic resonance imaging, a bone scan, and chest
radiography. All measurable diseases were reevaluated at 8-
week intervals. Radionuclide bone scans were repeated after
3 months. In all subjects, fasting venous blood samples wereProstate Cancer 3
drawn between 8.00 and 9.00 a.m. after a 12-h fasting period
at baseline and after 3 months in order to assess the bone
resorptionmarkercrosslinkedC-terminaltelopeptide(CTX)
and the bone formation marker bone alkaline phosphatase
(B-ALP).
In all cases, a baseline ECG was obtained, and a further
cardiac work-up was performed if indicated. Bone disease
progression was deﬁned as the appearance of any new bone
lesion or the progression of existing bone metastases. A
dental examination, including orthopantomography (OPT),
was performed in all patients at baseline, and active dental
surveillance every three months.
2.4. Treatment-Related Adverse Events. Toxicity was deﬁned
using the National Cancer Institute (NCI) Common Toxicity
Criteria, version 3.0. The treatment was delayed at the
ﬁrst occurrence of grade II hematological toxicity, and
administered at the same dose after it returned to grade
I or better. In the case of grade III or IV toxicity, the
treatment was interrupted and a maximum of three weeks
was allowed for recovery, after which the patients were
withdrawn from the study. In the case of a second episode
of grade III or IV toxicity in the same patient, treatment was
resumed after recovery and the subsequent administration
of D was reduced to 20mg/m2. Chemotherapy protocol was
discontinued if the ejection fraction decreased below the
institutional lower limit of normal and declined by ≥15%.
2.5. Statistical Considerations. The primary endpoint was
PSA response. In accordance with Simon’s “optimal design”,
a sample size of 36 patients was planned, assuming a
response rate of approximately 10% for other second-line
chemotherapies, and a target level of interest of 30%, with
an α of 0.05 and a β of 0.90. In the hypothesis of 10%–
20% inevaluable patients, about 40 patients were planned
to be enrolled to better estimate the response. Secondary
endpoints were pain response, progression-free survival
(PFS), and overall survival. PFS was deﬁned as the time from
starting chemotherapy to the ﬁrst occurrence of objective or
PSA progression, or death due to any cause.
3. Results
From September 2008 to April 2010, 43 patients were
enrolled. Their median age was 74 years (range 58–82 years)
Thirty-seven patients had bone metastases. and seventeen
patients had measurable disease (Table 1). Most of enrolled
patients have participated in a randomized phase II study
which compared the combination of weekly D and weekly
Epirubicin (EPI) with the conventional 3-weekly D [15]. All
patients who had achieved a response or a stable disease
during ﬁrst-line chemotherapy had been retreated with D-
based chemotherapy. The median dose of D received before
the enrollment in the current study was 940.8mg/m2 (range
30–1122,3).
All enrolled patients were treated with the new treatment
regimen within 60 days from the end of last D dose (range
12 to 52 days). Two patients received only one weekly
Table 2: Main patient characteristics.
Enrolled patients 43
Median age (range): years 74 (58–82)






Bone + prostate cancer 4
Bone + prostate cancer + lymph nodes 4
Bone + lung 3
Prostate cancer + lymph nodes 3
Liver + lymph nodes 2
Prostate cancer + lung 1








w-Epirubicin + w-docetaxel 21
3-w Docetaxel + prednisone 15
w-Docetaxel + prednisone 7




Docetaxel + prednisone 23
Best response to prior ﬁrst-line
chemotherapy










Median hemoglobin, g/dL 10.4
Range 7.9–13.8
chemotherapy cycle for treatment-unrelated reasons. Two
patients were lost to followup after four and six months
from the start of treatment. All patients were included in
the overall analysis (intent-to-treat). A total of 968 weekly D4 Prostate Cancer
Table 3: Response to treatment.
Enrolled patients 43
Biochemical response
PSA decline ≥50% 27 (62.8%)
Stable disease 9 (20.9%)
Progressive disease 7 (16.3%)
Objective response
Partial remission 8/17 (47.1%)
Stable disease 7/17 (41.1%)
Progressive disease 2/17 (11.8%)
Palliative response 31 (72.1%)
Table 4: Number of patients experiencing the most frequent
treatment-related adverse events.
Grade 1 Grade 2 Grade 3
Hematological
Neutropenia 19 (44.1%) 14 (32.5%) 8 (18.6%)
Anemia 20 (46.5%) 15 (34.8%) 6 (13.9%)
Thrombocytopenia 18 (41.8%) 12 (27.9%) 4 (9.3%)
Nonhematological
Nausea/vomiting 12 (27.9%) 8 (18.6%) 0
Diarrhea 9 (20.9%) 6 (13.9%) 0
Constipation 13 (30.2) 11(25.5%) 0
Nail changes 22 (51.1% ) 17 (39.5%) 2 (4.6%)
Dry eye/tearing 26 (60.4%) 15 (34.8%) 0
Myalgia/arthralgia 22 (51.1%) 14 (32.5%) 0
Fatigue 21 (48.8%) 18 (41.8%) 2 (4.6%)
Sensory neuropathy 16 (37.2%) 7 (16.2%) 0
Peripheral edema 22 (51.1%) 8 (18.6%) 0
Epistaxis 23 (53.4%) 7 (16.2%) 1 (2.3%)
Dyspnea 12 (27.9%) 5 (11.6%) 0
cycles (median 21, range 11–30) and a total of 1172 biweekly
cycles of Bev (median 26, range 6–41) were administered.
3.1. Biochemical Response. Ad e c r e a s ei nP S Al e v e l s>50%
was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91),
and nine patients (20.9%) had stable PSA for at least twelve
weeks (Table 3). After the ﬁrst 3 weekly cycles a PSA surge
was observed in 18 out of 27 responding patients: in all these
patients PSA then progressively decreased and at the third
month was less than 50% with respect to the baseline values
(Figure 1).
Duringthepriorﬁrst-linechemotherapy,15outofthe27
responding patients had achieved PSA response while 8 had
achieved stable disease and 4 patients had progressed.
3.2. Objective Response. Of seventeen patients with measur-
able disease, eight achieved PR and seven had stable disease:
objective responses were observed on prostate cancer (3
cases), prostate cancer and pelvic lymph nodes (3 cases), and
prostate cancer and lung metastases (2 cases).
The bone scan, which could be repeated after 3 months
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Figure 1: Median PSA (with minimum and maximum values) in
18 out of 27 responding patients who showed a PSA surge within
the ﬁrst 3 months of treatment with weekly D + biweekly Bev.
showed stable disease in 29 patients, and partial remission
in 5 patients; two or more new lesions compared with the
prior scan for trial entry were described in one patient.
This same patient had PSA progression after 3 months and
chemotherapy was stopped. The bone markers CTX and B-
ALP were reduced >50% with respect to baseline values in 33
and 28 patients, respectively, after 12 weeks from the start of
treatment (65% median reduction for CTX and 58% median
reduction for B-ALP). A palliative response was observed in
31 patients after 12 weeks (72.1%, 95% CI: to 0.48 to 1.02).
After 12 weeks from the start of the new treatment
protocol,sevenpatients(includingtwosubjectswhoreceived
only one treatment cycle) had PSA progression, but three
of them had a reduction in bone pain with decrease in
analgesics use, improvement in performance status, and
reduction in serum levels of the bone markers CTX and
BALP. Despite the initial end-point of the study, because
of the achieved clinical beneﬁt, our oncology group and
the scientiﬁc ethical committee decided to continue D +
Bev in these three patients until worsening of pain and/or
performance status.
After a median followup of 11.3 months, 18 patients
showed PSA progression and only ﬁve patients had died.
The regimen was generally well tolerated, and no unex-
pected toxic eﬀects were observed (Table 4). No grade 4 tox-
icity or congestive heart failure was observed, and all cycles
were administered on an outpatient basis. The most frequent
side eﬀects were neutropenia, anemia, thrombocytopenia,
epistaxis, and fatigue, which were grade I or II in most
cases. Grade III fatigue was observed in two patients after
nine and sixteen cycles, respectively: despite the reduction
of D dose and the discontinuation of Bev, treatment was
then interrupted in these cases because of the persistence
o ft h i ss i d ee ﬀect. Grade 1 epistaxis was observed in 23
patients (53.4%) during treatment, but reached grade 2 in
only 7 cases and grade 3 in one patient. No patient developed
osteonecrosis of the jaw (ONJ). Dose reduction of D was
required in a total of twelve patients: 37 (3.8%) weekly DProstate Cancer 5
cycles were administered with a 33% reduction, down to
20mg weekly. A total of 57 (5.8%) weekly D cycles were
delayed: the reason for the delays were hematological in 41
(71.9%) and nonhematological in 16 (28.1%) cycles. A total
of 46 (39.2%) biweekly Bev cycles were delayed: the reasons
for the delays were haematological in 39 (84.8%) and non-
hematological in 7 (15.2%) cycles.
4. Discussion
The currents phase II study is the ﬁrst extended report which
suggests that the combination of weekly D with the biweekly
administration of the antiangiogenic agent Bev is eﬀective
and tolerable in the treatment of patients with metastatic
CRPCwhohaveprogressedafterD-basedchemotherapy:the
62.7% PSA and 72.1% palliative response compare favorably
with the results observed in phase II studies of second-
line chemotherapy [16, 17]. Other chemotherapeutic agents
might be used after initial treatment with D, including old
drugs such as vinorelbine, oral cyclophosphamide, etopo-
side, mitoxantrone, vinblastine, and doxorubicin, but most
studies reported no objective response and less than 15%
laboratory response [18]. Other studies described modest
activity with satraplatin, a third-generation platinum analog,
or ixabepilone, an epothilone, with mitoxantrone, or also
with the combination of D and high-dose calcitriol [19–21].
It must be remembered that in most clinical trials a
few patients stop the ﬁrst-line treatment with D while still
responding to the drug. In this group of patients a repeated
treatment with D might be appropriated if progression
occurs after a reasonably long time interval [22]. In our
study, the strict eligibility requirement of progression while
on D or within 60 days of the last D dose means that
these patients might have not responded to rechallenge
with D. Notably, responses were seen also in patients who
had not shown an initial response to prior D as ﬁrst-line
treatment. Therefore, this ﬁnding and the characteristics
of enrolled patients support an eﬀective role of Bev in
restoring the sensitivity to D and also in reversing resistance
in patients who were previously nonresponders to the drug
(Table 1). Bev is able to alter tumor vasculature, for exam-
ple, decreasing tumor vessel permeability and increasing
intratumoral perfusion, which might turn into an improved
tumor delivery of a cytotoxic agent, thus enhancing its
antitumor activity [23]. Since the limited tissue penetration
is an important mechanism of tumor resistance to taxanes,
the eﬀects of the antiangiogenic agent Bev may be a possible
explanation of the observed reversal of D resistance in our
population study [24].
Another point to consider is the observed PSA surges
during treatment protocol in 18 out of 27 responding
patients, which may suggest massive cancer cell death and
PSA release, thus indicating eﬃcacy, as also reported in other
previous trials during chemotherapy for CRPC [25, 26].
Nevertheless, despite the unknown biological relevance of
this transient initial PSA increase, most of our patients
achieved an improvement in bone symptomatology and in
performance status, and PSA decreased > 50% at 3 months
(Figure 1). Furthermore, PSA results correlated with changes
in bone markers, since CTX and B-ALP were reduced with
respect to baseline values in all these patients, and this was
probably related to the real antitumor activity of the D + Bev
combination.
Notably, despite PSA progression after 3 months of treat-
ment, three patients continued to have an improvement in
performance status and reduction in bone symptomatology
and bone markers, and because of this achieved clinical
beneﬁt they continued to receive D + Bev. This ﬁnding
may conﬁrm that the progression criteria that are usually
suitable for assessment of eﬃcacy of cytotoxic agents in
CRPC may not be suitable for discriminating treatment
eﬀects of targeted agents such as Bev [27, 28]. It may be that
signiﬁcant treatment beneﬁts with targeted therapies need
long time scales to emerge, possibly due to its noncytotoxic-
targeted mechanism of action.
As Bev-based salvage treatment, a 55% PSA response
and 37.5% objective response was found in 20 pretreated
patients with CRPC receiving D 60mg/m2 and Bev 10mg/kg
every 3 weeks [9]. Another recent experience suggested a
beneﬁt in progression-free and in overall survival by the use
of weekly D 25mg/m2 combined with Bev 10mg/kg every
two weeks in CRPC patients [29]. The toxicity proﬁle of
our treatment protocol was comparable to that observed in
these BEV-based salvage treatments, with a major incidence
of grade IV neutropenia and thrombocytopenia reported
by the use of 3-weekly D schedule. Considering the strict
eligibility criteria of our study and the fact that all our
patients had previously received at least two chemotherapy
lines, the current results appear even more encouraging than
that found in the aforementioned reports. Nevertheless, it
must be considered that most of metastatic CRPC patients
who relapse after the ﬁrst line D and D rechallenge do not
survive more than 6 months. It is notable that in the current
study, after a median follow-up time of 11.3 months, only
ﬁve patients had died and most patients who started the new
treatment protocol more that 12 months ago are still alive
and have a good quality of life.
Therefore, although three-weekly D and P remains the
conventional treatment protocol in ﬁrst-line setting, it may
be hypothesized that weekly D combined with biweekly
Bev, as applied by us, is an appropriate schedule in terms
of activity and toxicity for heavily pretreated patients. The
combination of weekly scheduling of D with Bev has shown
interesting activity without signiﬁcant toxicity also in breast,
ovarian and mesenchymal tumors [30–32].
The eﬃcacy and safety results of the current study
compare favorably also with those reported with the drug
cabazitaxel, that was recently approved by US Food and
Drug administration for second-line treatment of metastatic
CRPC patients [3]. Severe neutropenia was common in
cabazitaxel trial (89%), and 18% of patients discontinued
the study treatment because of adverse events while grade
III neutropenia was observed in only 18.6% of cases in
our population study. Nevertheless toxicity was mild in our
patients: adverse events likely related to Bev (hypertension,
epistaxis, and albuminuria) never reached grade 3 and were
easily manageable, as usually reported in other tumors with6 Prostate Cancer
the biweekly schedule of 5mg/kg of Bev. The low toxicity of
D was mainly due to the weekly schedule. The eﬃcacy of
weekly D seems to be similar to that of the usual 3-weekly
schedule, but their comparative toxicities diﬀer markedly,
with moderate to severe myelosuppression being common
when the drug is administered once every 3 weeks [33].
As well as is concerned other adverse events, Altough the
new and potent antiangiogenic therapies might theoretically
enhance the antiangiogenic eﬀects of zoledronic acid on
bone tissue, our ﬁndings do not suggest a trend for a
possible higher incidence of bisphosphonate-induced ONJ
for patients receiving zoledronic acid and Bev [34].
Another point to consider is that the percentage of
enrolled patients ≥75 years was about 50% in the current
study, compared with only 18% in cabazitaxel trial. On these
ﬁndings, it seems that weekly D and biweekly Bev can be
safety administered also to elderly patients, who represent
the most part of CRPC population. Therefore, although
cabazitaxelwill be the only established second-line treatment
of CRPC patients in the next future, weekly D and Bev may
be a valid option for patients with a decreased hematological
reserve and/or for elderly subjects. Moreover, in the absence
of a randomized comparison between cabazitaxel and our
proposed treatment protocol, weekly D and Bev might be
used after cabazitaxel failure.
In conclusion the results of this study suggest that weekly
Da n db i w e e k l yB e vi sa ne ﬀective and well-tolerated treat-
ment option for patients with metastatic CRPC previously
exposed to D. Bev seems to overcome the resistance to the
drug in patients who had progressed during or after D-based
chemotherapy.
5. Conclusion
Weekly D + biweekly Bev seems to be an eﬀective and
well-tolerated treatment option for patients with metastatic
CRPC previously exposed to D-based chemotherapy.
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